ARCH Venture Partners

www.archventure.com/about

VCMatch tracks ARCH Venture Partners as an investor focused on Biotech, Pharma, and Medtech companies, Pre-Seed and Seed rounds, United States markets, and $50k check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$50k

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth

Focus Areas

Biotech, Pharma, Medtech

Geography

United States

Investment Thesis

ARCH is a science-first, founder/co‑founder oriented venture firm that takes a long-term, flexible approach to building transformative companies from fundamental research. The firm focuses on founding and commercializing breakthrough technologies out of academic institutions, corporate research groups and national labs, pairing “great science with remarkable, proven teams” and sizing capital from seed-level ($50K) up through hundreds of millions as needed to give each technology the best chance to advance.

Is ARCH Venture Partners right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

ARCH Venture Partners is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Medtech, and Digital Health, especially across United States, with public check-size signals around $50k.

Focus statement

ARCH invests primarily in early-stage advanced technology and biotechnology companies formed around breakthrough or revolutionary technologies addressing major health and physical‑science challenges (infectious disease, mental health, immunology, oncology, neurology, age‑related disease, genomic and biological tools, data sciences, diagnostics, manufacturing and clinical trials).

Value Add

Co-founding model: "ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs" — they originate and build companies, not just passively fund them.
Extremely flexible, multi-stage capital: they state they will "invest at all levels, whether it’s fifty thousand dollars or hundreds of millions," and use fund/overage structures (e.g., Fund X and Fund X Overage) to support larger follow‑on needs.
Deep commercialization expertise for academic and lab‑based inventions: described as "a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories."
Willingness to start from raw science: "ARCH is still willing to sit down with a scientist with a lab notebook to develop and translate great science into great companies."
Long track record and scale: over 30+ years and numerous marquee portfolio companies (Illumina, Alnylam, Juno, Twist, etc.), plus large recent funds (Fund XII $2.975B) demonstrating capacity to back companies through long growth cycles.